January 12, 2017 / 4:59 AM / 7 months ago

BRIEF-Tesaro receives complete response letter for Rolapitant IV from U.S. FDA

Jan 11 (Reuters) - Tesaro Inc :

* Tesaro receives complete response letter for Rolapitant IV from U.S. FDA

* No concerns raised by FDA related to Rolapitant IV efficacy or safety profile and additional clinical studies are not required

* CRL did not identify concerns related to safety or efficacy of Rolapitant IV or request additional clinical studies Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below